Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer Treatment: Insights from the TOPAZ-1 Trial

Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer Treatment: Insights from the TOPAZ-1 Trial

Biliary tract cancers (BTCs) are a difficult-to-treat group of tumors with an overall poor prognosis. Until 2022, combination chemotherapy was the first-line treatment standard for patients with advanced BTCs, achieving a moderate patient survival improvement. The evolution of chemoimmunotherapy has...

Full description

Saved in:

Bibliographic Details
Main Author:	Ralph Fritsch
Format:	Article
Language:	English
Published:	THE HEALTHBOOK COMPANY LTD. 2024-10-01
Series:	healthbook TIMES. Oncology Hematology
Online Access:	https://doi.org/10.36000/HBT.OH.2024.21.157
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost-effectiveness analysis of durvalumab with chemotherapy and maintenance durvalumab with or without olaparib for advanced endometrial cancer
by: Jiahao Zhang, et al.
Published: (2025-01-01)

The Immune Landscape and Its Potential for Immunotherapy in Advanced Biliary Tract Cancer
by: Andry Santoso, et al.
Published: (2024-12-01)

Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation–Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE)
by: Chee Khoon Lee, PhD, et al.
Published: (2025-02-01)

Serum 25‐Hydroxyvitamin D Levels and Survival Outcomes in Advanced Biliary Tract Cancer: Results From the NIFTY Trial
by: So Heun Lee, et al.
Published: (2025-01-01)

Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trialResearch in context
by: Abha A. Gupta, et al.
Published: (2025-01-01)

Color Dependence on Thickness in Topaz Crystal from Brazil
by: Waldemar Bonventi Jr, et al.
Published: (2012-01-01)

TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2− breast cancer
by: Heather L. McArthur, et al.
Published: (2025-02-01)

Helicobacter pylori and Biliary Tract Cancers: A Meta-Analysis
by: Soumia Cherif, et al.
Published: (2020-01-01)

Integration of circulating tumor DNA in biliary tract cancer: the emerging landscape
by: Joy A Awosika, et al.
Published: (2024-12-01)

The Emerging Role of miRNAs and Their Clinical Implication in Biliary Tract Cancer
by: Nina Nayara Ferreira Martins, et al.
Published: (2016-01-01)

Recent advances in systemic therapy for advanced biliary tract cancer: A systematic review and meta-analysis using reconstructed RCT survival data
by: Zhihao Li, et al.
Published: (2025-03-01)

Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study
by: Pernelle Lavaud, et al.
Published: (2025-01-01)

ABOUT THE COMPOSITION AND NEUTRON ACTIVATION RADIOGRAPHY OF TOPAZ CRYSTALS FROM AN AUTHOR’S COLLECTION
by: V.I. Popova, et al.
Published: (2024-09-01)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in the Chinese healthcare system
by: Wenwang Lang, et al.
Published: (2025-01-01)

Efficacy of Neoadjuvant Chemotherapy with Capecitabine plus Oxaliplatin in the Treatment of Locally Advanced Sigmoid Colon Cancer Invading the Urinary Bladder: A Report of Three Cases
by: Tsutomu Takenami, et al.
Published: (2019-01-01)

Impact of corticosteroids on the efficacy of first-line pembrolizumab plus chemotherapy in patients with advanced non-small-cell lung cancer
by: Amytis Roboubi, et al.
Published: (2025-02-01)

Efficacy and safety of neoadjuvant bevacizumab plus chemotherapy in locally advanced gastric cancer patients: a retrospective, comparative study
by: Bin Yin, et al.
Published: (2025-01-01)

Gallbladder Agenesis without Additional Biliary Tracts Abnormality
by: Seyed Mostafa Meshkati Yazd, et al.
Published: (2022-01-01)

Somatic Mutations from Whole Exome Sequencing Analysis of the Patients with Biliary Tract Cancer
by: Kyong-Ah Yoon, et al.
Published: (2018-12-01)

Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China.
by: Chaoneng He, et al.
Published: (2024-01-01)

Targeting Interleukin-4 Receptor Alpha by Hybrid Peptide for Novel Biliary Tract Cancer Therapy
by: Kahori Seto, et al.
Published: (2014-01-01)

Fasciolopsis buski infection of the biliary tract: a case report
by: Shuai Luo, et al.
Published: (2025-01-01)

Perioperative tislelizumab plus chemotherapy for locally advanced gastroesophageal junction adenocarcinoma (NEOSUMMIT-03): a prospective, nonrandomized, open-label, phase 2 trial
by: Run-Cong Nie, et al.
Published: (2025-02-01)

Brief report: impact of consolidation durvalumab on unresectable non-small cell lung cancer with driver mutations
by: Jason C.S. Ho, et al.
Published: (2024-01-01)

Long-term efficacy and safety of alemtuzumab in participants with highly active MS: TOPAZ clinical trial and interim analysis of TREAT-MS real-world study
by: Tjalf Ziemssen, et al.
Published: (2025-02-01)

Utility and clinical significance of endoscopic ultrasound-guided tissue acquisition for diagnosing lymphadenopathies in biliary tract cancer
by: Katsuhiko Sato, et al.
Published: (2025-01-01)

The Role of Chemotherapy in Upper Tract Urothelial Carcinoma
by: Peter H. O&#39;Donnell, et al.
Published: (2009-01-01)

Functional Disorders of the Biliary Tract and Cholelithiasis: Analysis of a Possible Relationship
by: Yu. O. Shulpekova, et al.
Published: (2024-10-01)

Lipid Metabolism Alterations in Hyperlipidemic Dogs with Biliary Tract or Endocrine Diseases
by: Tae-Woo Kim, et al.
Published: (2025-01-01)

TAS-102 Plus Bevacizumab as an Effective and Well Tolerated Regimen in Chemotherapy-Refractory Advanced Colorectal Cancers – A Single Institution Retrospective Analysis
by: Ritam Joarder, et al.

Proceedings of clinical trials on bile tract cancer
by: XIONG Yichen, YANG Ziyi, SANG Yuer, GONG Wei
Published: (2024-09-01)

Editorial: Advances in immunotherapy of hepatic-biliary-pancreatic cancers, volume II
by: Hu Jiaming, et al.
Published: (2025-01-01)

Prognostic Factors of Radiofrequency Ablation plus Systemic Chemotherapy for Unresectable Colorectal Cancer with Liver Metastasis
by: Ky Thai Doan, et al.
Published: (2020-01-01)

Serum NGAL to Clinically Distinguish Cholangiocarcinoma from Benign Biliary Tract Diseases
by: Kawin Leelawat, et al.
Published: (2011-01-01)

An analysis of the global burden of gallbladder and biliary tract cancer attributable to high BMI in 204 countries and territories: 1990–2021
by: Zhuowen Hu, et al.
Published: (2024-12-01)

Diversity of TCR repertoire predicts recurrence after CRT followed by durvalumab in patients with NSCLC
by: Masayuki Shirasawa, et al.
Published: (2025-01-01)

Enterococcus Faecalis Endocarditis Following Percutaneous Manipulation of a Biliary Tract Calculus and ERCP
by: Allan R Ronald, et al.
Published: (1990-01-01)

Study protocol of the METAPANC trial - intensified treatment in patients with local operable but oligometastatic pancreatic cancer - multimodal surgical treatment versus chemotherapy alone: a randomized controlled trial
by: Michael Ghadimi, et al.
Published: (2025-02-01)

Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia
by: Marlise R. Luskin, et al.
Published: (2025-02-01)

Efficacy of PD-1 blockade plus chemotherapy in patients with oncogenic-driven non-small-cell lung cancer
by: Haowei Wang, et al.
Published: (2025-02-01)